Effects of Common Antihypertensive Class Medications on BMI z‐Score in Adolescents
Pediatric Obesity · 2026-05 · 21 (5)
DOI: 10.1111/ijpo.70114 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Obesity, online erschienen am 21.05.2026. Verfasst von Matthew F Daley und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Antihypertensive Agents, Body Mass Index, Hypertension. Die Arbeit nennt 34 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Background
Antihypertensive class medications are prescribed long‐term for adolescents, including for conditions other than hypertension. Evidence on weight effects is limited.
Objective
To assess the weight effects of commonly prescribed antihypertensive class medications among adolescents, regardless of clinical indication for use.
Methods
This retrospective study was conducted using electronic health record (EHR) data from a multi‐site US research network. The study cohort included adolescents aged 13.0–19.5 years with ≥ 1 antihypertensive class medication order during 2010–2019. Weight and height documented in the EHR were used to calculate BMI z‐scores. Inverse probability weighting with marginal structural models was used to account for selection factors and covariates.
Results
Overall, 23 853 adolescents were prescribed an antihypertensive class medication, including clonidine (prescribed to n = 7491), guanfacine ( n = 6411), lisinopril ( n = 3584), propranolol ( n = 3015), spironolactone ( n = 1926), and atenolol ( n = 1426). At baseline, 13% had a hypertension diagnosis. At 12 months after medication initiation, the estimated population‐level BMI z‐score was significantly increased for propranolol (BMI z‐score 0.19 [95% CI 0.09, 0.29]) and significantly decreased for lisinopril (−0.06 [95% CI −0.10, −0.01]); clonidine, guanfacine, spironolactone, and atenolol were not associated with a significant change in BMI z‐score.
Conclusions
Most antihypertensive class medications were not associated with statistically significant weight gain when prescribed to adolescents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
- Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
- Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Faith Family Medical Center, Nashville, Tennessee, USA.
- Applied Clinical Research Center, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Matthew F Daley, Sheryl L Rifas-Shiman, Jessica G Young, Joshua Petimar, Carly Prentice, L Charles Bailey, David M Janicke, William J Heerman, Jason P Block
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Daley, M. F., Rifas-Shiman, S. L., Young, J. G., Petimar, J., Prentice, C., Bailey, L. C., Janicke, D. M., Heerman, W. J., & Block, J. P. (2026). Effects of Common Antihypertensive Class Medications on BMI z‐Score in Adolescents. Pediatric Obesity, 21(5). https://doi.org/10.1111/ijpo.70114
Vancouver
Daley MF, Rifas-Shiman SL, Young JG, Petimar J, Prentice C, Bailey LC, et al. Effects of Common Antihypertensive Class Medications on BMI z‐Score in Adolescents. Pediatric Obesity. 2026;21(5). doi:10.1111/ijpo.70114
BibTeX
@article{Daley2026,
author = {Daley, Matthew F and Rifas-Shiman, Sheryl L and Young, Jessica G and Petimar, Joshua and Prentice, Carly and Bailey, L Charles and Janicke, David M and Heerman, William J and Block, Jason P},
title = {Effects of Common Antihypertensive Class Medications on BMI z‐Score in Adolescents},
journal = {Pediatric Obesity},
year = {2026},
volume = {21},
number = {5},
doi = {10.1111/ijpo.70114}
}
EUVIMED